marcia brose, md, phd, describes how testing for trk abnormalities are accomplished
Published 4 years ago • 17 plays • Length 4:33Download video MP4
Download video MP3
Similar videos
-
2:39
marcia brose, md, phd, provides opinion on who should be tested trk fusions
-
1:08
marcia brose, md, phd, on biopsy requirements for optimal evaluation for actionable trk fusions
-
0:48
marcia brose, md, phd, provides an overview of trk fusion treatment in cancer patients
-
1:42
marcia brose, md, phd, expounds on what should be done for patients who progress on larotrectinib
-
1:14
marcia brose, md, phd, discusses the dosing, safety and efficacy of larotrectinib reported at asco20
-
0:54
genomic testing recommended for patients with thyroid cancer
-
5:39
marcia s. brose, md, phd: the stigma of thyroid cancer
-
16:39
life after thyroidectomy/thyroid cancer (16 months)
-
4:35
nancy's story - thyroid cancer survivor
-
21:47
molecular testing for thyroid nodules sd 480p
-
3:01
dr. marcia brose - medical oncologist
-
9:23
marcia s. brose, md, phd: all about thyroid cancer
-
2:34
new hope for patients with thyroid cancer: spotlight on marcia brose, md, phd
-
0:57
dr. brose describes the decision trial
-
6:22
a overview of thryoid cancer with marcia brose, md, phd
-
1:14
thyroid cancer awareness month: marcia brose, md, phd
-
1:17
dr. marcia brose discusses lenvatinib as a new option in dtc
-
1:59
dr. marcia brose describes sorafenib in rai-resistant differentiated thyroid cancer
-
1:02
dr. brose discusses updated overall survival analysis of the decision trial
-
7:48
marcia s. brose, md, phd: advances in thyroid cancer, the decison trial
-
1:02
larotrectinib efficacy highlights importance of genomic testing in thyroid cancer
-
1:56
dr. brose on vandetanib for differentiated thyroid cancer